Search This Blog

Saturday, July 23, 2016

Amgen And UCB Submit Biologics License Application For Romosozumab To The FDA

Based on Phase 3 FRAME Study in Postmenopausal Women With Osteoporosis



Amgen - Investors - RSS Content

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.